Colchicine for epidermolysis bullosa acquisita.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 8632074.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal blistering disease that is difficult to treat. Recently one patient with severe EBA was described who responded dramatically to colchicine. Our purpose was to determine the efficacy of colchicine in the treatment of EBA. Four patients with severe EBA refractory to conventional therapy were treated with colchicine 0.6 to 1.5 mg a day for up to 4 years. In all four patients the lessening of skin fragility and the decrease in spontaneous blister formation were dramatic; few side effects were noted. Colchicine should be considered in the treatment of EBA.
Medical subject headings
- Colchicine
- Dermatologic Agents
- Epidermolysis Bullosa Acquisita